Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetateIn 2021, Rocco, Patricia R. M.;Silva, Pedro L.;Cruz, Fernanda F.;Melo, Marco Antonio C. Jr.;Tierno, Paulo F. G. M. M.;Moura, Marcos A.;De Oliveira, Luis Frederico G.;Lima, Cristiano C.;Santos, Ezequiel A. Dos;Walter, F. Jr.;Fernandes, Ana Paula S. M.;Franchini, Kleber G.;Magri, Erick;de Moraes, Nara F.;Goncalves, Jose Mario J.;Carbonieri, Melanie N.;Santos, Ivonise S. Dos;Paes, Natalia F.;Maciel, Paula V. M.;Rocha, Raissa P.;de Carvalho, Alex F.;Alves, Pedro Augusto;Proenca-Modena, Jose Luiz;Cordeiro, Artur T.;Trivella, Daniela B. B.;Marques, Rafael E.;Luiz, Ronir R.;Pelosi, Paolo;e Silva, Jose Roberto Lapa published 《Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial》. 《European Respiratory Journal》published the findings. The article contains the following contents:
Background: Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation and hospitalisation rate. Adverse events were also assessed. Results: From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analyzed. Median (interquartile range) time from symptom onset to first dose of study drug was 5 (4-5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were neg. for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm vs. 18.2% in the placebo arm (p = 0.009). Viral load was reduced after nitazoxanide compared to placebo (p = 0.006). The percentage viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p = 0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed Conclusions: In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.
2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate
Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica